Table 1 Toxicities associated with administration of R115777
From: Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
| Â | Grade of Adverse Event | |||
|---|---|---|---|---|
2 | 3 | 4 | 5 | |
n (%) | n (%) | n (%) | n (%) | |
Hematologic Adverse Events | Â | Â | Â | Â |
Anemia | 1 (8) | 1 (8) | 0 (0) | 0 (0) |
Leukopenia | 2 (17) | 0 (0) | 0 (0) | 0 (0) |
Neutropenia | 0 (0) | 1 (8) | 1 (8) | 0 (0) |
 Maximum Hematologic AEs | 1 (8) | 1 (8) | 1 (8) | 0 (0) |
Non-Hematologic Adverse Events | Â | Â | Â | Â |
Constitutional | Â | Â | Â | Â |
Fatigue | 4 (33) | 0 (0) | 0 (0) | 0 (0) |
Gastrointestinal | Â | Â | Â | Â |
Anorexia | 1 (8) | 1 (8) | 0 (0) | 0 (0) |
Dehydration | 0 (0) | 1 (8) | 0 (0) | 0 (0) |
Diarrhea | 1 (8) | 0 (0) | 0 (0) | 0 (0) |
Nausea | 1 (8) | 1 (8) | 0 (0) | 0 (0) |
Vomiting | 1 (8) | 1 (8) | 0 (0) | 0 (0) |
Metabolic | Â | Â | Â | Â |
Creatinine | 0 (0) | 1 (8) | 0 (0) | 0 (0) |
Hyperglycemia | 1 (8) | 0 (0) | 0 (0) | 0 (0) |
Neuropathy | 1 (8) | 0 (0) | 0 (0) | 0 (0) |
Pain | 1 (8) | 0 (0) | 0 (0) | 0 (0) |
Dyspnea | 1 (8) | 0 (0) | 0 (0) | 0 (0) |
Maximum Non-Hematologic AE | 5 (42) | 2 (17) | 0 (0) | 0 (0) |
Overall Adverse Events | 5 (42) | 2 (17) | 1 (8) | 0 (0) |